<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33579690</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-2079</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>106</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>The British journal of ophthalmology</Title>
          <ISOAbbreviation>Br J Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Improvement of asymmetric thyroid eye disease with teprotumumab.</ArticleTitle>
        <Pagination>
          <StartPage>755</StartPage>
          <EndPage>759</EndPage>
          <MedlinePgn>755-759</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/bjophthalmol-2020-318314</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Teprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in patients with asymmetric TED. Herein, we investigate the differential impact of teprotumumab on the orbits of such patients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this pooled analysis of patients who were enrolled in the recent phase 2 (NCT01868997) and phase 3 (NCT03298867) trials, all patients with asymmetric TED (difference in exophthalmometry of ≥3 mm) were screened for eligibility. The primary outcomes of the trials, proptosis, diplopia and Clinical Activity Score (CAS) response, were evaluated in both orbits of patients who had received treatment or placebo, to examine the differential response from baseline to week 24.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">From a pooled group of 84 patients randomised to receive teprotumumab and 87 randomised to placebo, 10 (12%) and 12 (14%), respectively, met the inclusion criteria. The teprotumumab-treated patients demonstrated significant reductions in proptosis, CAS and diplopia in both orbits of each patient and this was not seen with placebo. The reduction in proptosis and CAS was significantly greater in the worse affected orbit, improving symmetry. In the placebo arm, while the mean CAS in the study eye reduced over time, proptosis and diplopia did not change in either orbit.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings in this study suggest the differential impact of teprotumumab on orbits that are clinically more affected by TED, suggesting that teprotumumab reduces asymmetry.</AbstractText>
          <CopyrightInformation>© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ugradar</LastName>
            <ForeName>Shoaib</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-4479-3033</Identifier>
            <AffiliationInfo>
              <Affiliation>Orbital and Ophthalmic Plastic Surgery, Jules Stein Eye Institute, Los Angeles, California, USA ugradsahi@aol.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Oculoplastics, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mester</LastName>
            <ForeName>Tunde</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Oculoplastics, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kahaly</LastName>
            <ForeName>George J</ForeName>
            <Initials>GJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Douglas</LastName>
            <ForeName>Raymond</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Ophthalmology, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Ophthalmol</MedlineTA>
        <NlmUniqueID>0421041</NlmUniqueID>
        <ISSNLinking>0007-1161</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Y64GQ0KC0A</RegistryNumber>
          <NameOfSubstance UI="C551399">teprotumumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004172" MajorTopicYN="N">Diplopia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005094" MajorTopicYN="Y">Exophthalmos</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">eye (globe)</Keyword>
        <Keyword MajorTopicYN="Y">eye lids</Keyword>
        <Keyword MajorTopicYN="Y">immunology</Keyword>
        <Keyword MajorTopicYN="Y">orbit</Keyword>
        <Keyword MajorTopicYN="Y">pathology</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: RD: Consultant Horizon Therapeutics, Immunovant. GK: The JGU Medical Centre has received research-associated funding from Horizon Therapeutics.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>13</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33579690</ArticleId>
        <ArticleId IdType="doi">10.1136/bjophthalmol-2020-318314</ArticleId>
        <ArticleId IdType="pii">bjophthalmol-2020-318314</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
